INDIA MARKET LENS

Aurobindo Pharma Limited (AUROPHARMA): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Aurobindo Pharma Limited, explained in plain English.

  • Aurobindo Pharma Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • AUROPHARMA closed at ₹1,795.00 on 18 November 2026.
  • Over the past year the shares are up 45.1%, trading between ₹1,106.00 and ₹1,859.90.
  • Reported fundamentals show return on equity of 10.71%, a net margin of 10.81%, debt to equity of 21.9.
  • Our Pulse grade checklist scores it C (63/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
  • Annualised volatility over the past year is 26.35% with a maximum drawdown of -9.7% and a beta of 0.41 against NIFTY 50.
  • Recent coverage: Diwali Muhurat trading stocks+ dividend: Expert picks 2 stocks for Samvat 2083 with record dates next week - Do you own?
  • Recent coverage: Cracker stocks this Diwali! Axis Direct selects 10 technical stock with 48% upside potential for Samvat 2083
  • Recent coverage: Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Biocon

Figures from the current session. Market open.

Aurobindo Pharma Limited (AUROPHARMA)

₹1,795

▲ 0.9 (+0.05%)

Price & volume

AUROPHARMA price chart, 1Y range. 252 points from 2025-11-19 to 2026-11-18. Opens at 1,235.8, closes at 1,795, ranging between 1,121.7 and 1,855.3.1,2001,4001,6001,800Nov-25Jan-26Mar-26Apr-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Strong momentum · 5/5
✓ Above 50-day avg✓ Above 200-day avgRSI 60.6 · healthyMACD positiveBollinger %B 69ADX 29.4 · strong trend

1M

+7.68%

3M

+9.12%

6M

+19.63%

1Y

+44.84%

Where it sits in its 52-week range

92%
₹1,121.7₹1,855.3

Below 52-week high

3.3%

60.0% above the low

Momentum read

Strong

5/5 checks passed

52-wk high

₹1,855.3

52-wk low

₹1,121.7

Market cap

₹1,03,229 Cr

P/E (trailing)

26.0

Dividend yield

—

ROE

10.71%

Profit margin

10.81%

Revenue growth

23.9%

Price / Book

2.62

Debt / Equity

21.9

EPS (TTM)

69.05

Book value

₹684.73

Beta

0.41

Pulse grade: C, 63 out of 100

Momentum

A
  • ✓Trading above 50-day average
  • ✓Trading above 200-day average
  • ✓RSI in healthy 45-70 zone
  • ✓Positive 3-month return

Growth

A
  • ✓Revenue growth above Pharma & Healthcare median (20.8%)
  • ✓Revenue growing above 5%
  • ✓Quarterly profits trending up

Profitability

F
  • ✕Return on equity above Pharma & Healthcare median (14.64%)
  • ✕Return on equity above 12%
  • ✕Profit margin above Pharma & Healthcare median (13.82%)

Safety

D
  • ✕Debt below Pharma & Healthcare median (18.57)
  • ✓Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹10,227 crore · net profit ₹1,126 crore · margin 11.0%

10,2270Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,870.6+0.03%-6.52%
DRREDDY1,383.8+0.43%-0.30%
CIPLA1,393.3+0.38%-9.27%
DIVISLAB11,216.5+0.60%-3.02%
APOLLOHOSP8,770-0.01%-3.30%
LUPIN1,959.1+0.47%-22.10%

AUROPHARMA headlines

No AUROPHARMA stories right now.

AUROPHARMA filings & announcements

Reading the exchange…

AUROPHARMA, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

26.35%

Sharpe ratio

1.32

Sortino ratio

2.04

Max drawdown

-9.7%

Daily VaR (95%)

-2.28%

CAGR (1Y)

45.47%

Return skew

0.04

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.